AllSci News
Trump cuts US childhood vaccine schedule, targets MMR
Category: Regulatory Policy | Regulatory Body: HHS | Geography: United States | Policy Instrument: Executive Order
Scripps developing three-antigen nanoparticle platform for universal flu vaccine
Scripps Research Institute has received a USD 3.68 million NIAID R01 grant to develop a multicomponent self-assembling protein nanoparticle platform...
MoonLake's sonelokimab meets all endpoints in Phase III psoriatic arthritis trial
MoonLake Immunotherapeutics (Nasdaq: MLTX) reported positive Week 16 topline results from the Phase III IZAR-1 trial of sonelokimab in biologic-naïve...
Silence's divesiran achieves 88% response in Phase II PV trial with quarterly dosing
Silence Therapeutics plc (Nasdaq: SLN) reported positive topline results from the Phase II SANRECO trial of divesiran in polycythemia vera (PV) on August...
AbCellera's NK3R antibody meets both endpoints in Phase II menopause study
AbCellera Biologics (Nasdaq: ABCL) reported that ABCL635, its investigational neurokinin 3 receptor (NK3R) antagonist antibody, met both primary efficacy...
FDA blocks ITM's radiotherapy drug over manufacturing defects, clinical data intact
Germany-based ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, for its New Drug Application...
Almirall taps CrystalO's AI platform to discover ion channel drugs for skin disease
Barcelona-based Almirall, S.A. (ALM) and China-based Shenzhen CrystalO Biopharma Technology Co., Ltd. have announced a collaboration and licensing agreement...
Sobi funds Innate's phase III lacutamab trial with USD 75 million upfront deal
Marseille-based Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI) announced a strategic...
Sionna's lead cystic fibrosis program fails Phase IIa test, clouding NBD1 stabilizer strategy
Sionna Therapeutics (Nasdaq: SION) reported on August 10 that its lead cystic fibrosis program has failed its first test in patients, forcing a strategic...
Novo Nordisk taps AWS as preferred cloud provider, launches London AI drug discovery hub
Novo Nordisk (Copenhagen: NOVO B) and Amazon Web Services (AWS) announced a strategic partnership that establishes AWS as Novo Nordisk's preferred cloud...
Tenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF
Tenax Therapeutics (Nasdaq: TENX) reported on August 10 that the Phase III LEVEL trial of levosimendan — a calcium sensitizer and ATP-sensitive potassium...
NIH backs Yale's non-viral CRISPR platform for neurological gene editing
Yale University has received a USD 3.5 million NIH supplement award to advance a non-viral CRISPR delivery platform toward a first-in-human Phase I safety...
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) and Revolution Medicines, Inc. (Nasdaq: RVMD) announced a two-part arrangement covering both...
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel
Menlo Park, California-based GRAIL, Inc. (Nasdaq: GRAL) has announced that the US FDA's Molecular and Clinical Genetics Panel of the Medical Devices...
Stanford researchers uncover blood-to-brain immune cell migration in human aging
Researchers at Stanford Medicine have identified a previously unrecognized phenomenon in which peripheral blood-derived immune cells migrate into the human...
The AllSci Brief
Free, systematic R&D and deal news. Daily.